Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01456416 · ClinicalTrials.gov registry record
Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities
A clinical trial of Relapsing Remitting Multiple Sclerosis, sponsored by University of Southern California.
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT01456416 is a study of Relapsing Remitting Multiple Sclerosis that has completed, run by University of Southern California. The registered enrollment target is 10 participants, below the 202-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01456416, a study of Relapsing Remitting Multiple Sclerosis, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The incidence of autoimmune conditions is at least 2-3 times higher in Multiple Sclerosis population than in general population. These MS patients category response unfavorably to the Interferon. The investigators suggest that autoimmune co morbidity can serve as a biological marker predicting good response to GA.
Conditions Studied
Study Locations (1)
California
- USC MS Comprehensive Care Center & Research Group - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01456416
The ClinicalTrials.gov registry entry for NCT01456416 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (95% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT01456416 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01456416 about?
NCT01456416 is a clinical study titled "Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities". The incidence of autoimmune conditions is at least 2-3 times higher in Multiple Sclerosis population than in general population. These MS patients category response unfavorably to the Interferon. The investigators suggest that autoimmune co morbidity can serve as a biological marker predicting good ...
What is the current status of trial NCT01456416?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2011-09. Estimated completion is 2013-04.
What conditions does trial NCT01456416 study?
This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.
Who is sponsoring clinical trial NCT01456416?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01456416 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Remitting Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
RECRUITING
-
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
RECRUITING
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
RECRUITING · NA
-
Functional Outcomes From Diets in Multiple Sclerosis
RECRUITING · NA
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.